Back to Search
Start Over
Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.
- Source :
- Vaccines; May2021, Vol. 9 Issue 5, p428, 1p
- Publication Year :
- 2021
-
Abstract
- We describe the results of two vaccinations of a self-experimenting healthy volunteer with SARS-CoV-2-derived peptides performed in March and April 2020, respectively. The first set of peptides contained eight peptides predicted to bind to the individual's HLA molecules. The second set consisted of ten peptides predicted to bind promiscuously to several HLA-DR allotypes. The vaccine formulation contained the new TLR 1/2 agonist XS15 and was administered as an emulsion in Montanide as a single subcutaneous injection. Peripheral blood mononuclear cells isolated from blood drawn before and after vaccinations were assessed using Interferon-γ ELISpot assays and intracellular cytokine staining. We detected vaccine-induced CD4 T cell responses against six out of 11 peptides predicted to bind to HLA-DR after 19 days, following vaccination, for one peptide already at day 12. We used these results to support the design of a T-cell-inducing vaccine for application in high-risk patients, with weakened lymphocyte performance. Meanwhile, an according vaccine, incorporating T cell epitopes predominant in convalescents, is undergoing clinical trial testing. [ABSTRACT FROM AUTHOR]
- Subjects :
- MONONUCLEAR leukocytes
SARS-CoV-2
VACCINES
T cells
Subjects
Details
- Language :
- English
- ISSN :
- 2076393X
- Volume :
- 9
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 150502888
- Full Text :
- https://doi.org/10.3390/vaccines9050428